AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
GT Biopharma Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S80Y31
5.46▼ 0.06 (-1.09%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
5.52
Day's Range
5.31 – 5.70
52-Week Range
0.22 – 11.98
Volume
63.1K
Avg Volume
78.4K
Share Statistics
Shares Outstanding
Employees
1
Exchange
XNAS
Listed
2021-02-11
Share count as of August 10, 2026

GT Biopharma Inc. Common Stock (GTBP) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about GT Biopharma Inc. Common Stock (GTBP)
What is GT Biopharma Inc. Common Stock's Market Cap?
GT Biopharma Inc. Common Stock's Market Cap is $246.3M, based on as-reported figures from SEC (XBRL) filings.
What is GT Biopharma Inc. Common Stock's Revenue (TTM)?
GT Biopharma Inc. Common Stock's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is GT Biopharma Inc. Common Stock's Net Income (TTM)?
GT Biopharma Inc. Common Stock's Net Income (TTM) is -$4.8M, based on as-reported figures from SEC (XBRL) filings.
What is GT Biopharma Inc. Common Stock's Diluted EPS (TTM)?
GT Biopharma Inc. Common Stock's Diluted EPS (TTM) is -0.11, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · GTBPAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue————
Operating Expenses:
Research and Development Expense
Selling, General and Administrative Expense
Loss from Operations
Other Income (Expense)
Interest Income
Interest expense—
Loss on initial recognition of Greenshoe Rights liability——
Change in fair value of warrant liability
Non-Operating Income (Expense)——
Total Other Income (Expense), net
Net Loss
Dividend on preferred stock——
Deemed dividend
Net Loss attributable to common stockholders’
Earnings Per Share (Basic)—
Earnings Per Share (Diluted)—